Oncology Central

Melanomas’ fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach?


Early-stage cutaneous melanoma is curable but advanced, metastatic melanoma is almost uniformly fatal [1]. Patients with such advanced disease have a short median survival of only 6–9 months [2]. Not only is cutaneous melanoma responsible for 75–80% of skin cancer deaths but there is an ongoing ‘melanoma epidemic’ [3].

Detecting and excising melanoma early is key to improving survival and melanoma is characterized by clinical and biological heterogeneity, which in part explains why melanoma is notoriously resistant to chemo- and immuno-therapeutic strategies [4,5].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.